Studies have shown that targeting ASCT2‐mediated glutamine uptake via specific inhibitors or ASCT2‐siRNA can reduce tumor growth and development in endometrial, prostate, and colorectal cancer.7, 10, 15 Furthermore, previous studies have reported that ASCT2 may be used as a potential molecular marker to predict poor prognosis in non–small cell lung cancer and esophageal squamous cell carcinoma.8 In breast cancer, high expression of ASCT2 is associated with poor recurrence‐free survival.16 Here, SLC1A5 is linked to neoplasm.